Event Participants
Executives
2 Ramswaroop Radheshyam Thard, Sunil Sharma
Analysts
4 Abhi Jain, Agastya Dave, Amit Mehendale, Nishita Shanklesha
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹102.91 crores | Highest-ever quarterly revenue; +24.72% YoY vs ₹82.52 crores, driven by strong domestic recovery and better product mix |
| Domestic Revenue | ₹91.19 crores | +31.9% YoY from ₹69.12 crores; strong recovery in domestic packaging demand |
| Export Revenue | ₹11.72 crores | Flat YoY; impacted by continued geopolitical uncertainties across international markets |
| EBITDA | ₹16.52 crores | +36.75% YoY from ₹12.08 crores; driven by operating efficiencies and scale |
| EBITDA Margin | 16.05% | Improved +141 bps YoY from 14.64%; helped by better product mix and capacity utilization |
| PAT | ₹7.25 crores | +76.83% YoY from ₹4.10 crores; PAT margin improved to 7.04% from 4.97% |
| Injection Moulding Revenue Mix | 12.3% of revenue | Down from 15.6% in Q1 FY26; 60% of IM sales are exports, disrupted by geopolitical issues - expected to recover to 15-16% in 1-2 quarters |
| Injection Moulding Capacity | 5,800 MT | Added 1,000 MT during quarter; 5.8x increase since FY23 |
| Sleeving Capacity | 1,675 lakh units/annum | Expanded from 1,275 lakh units/annum during the quarter |
Geographic & Segment Commentary
Packaging (Rigid Plastics): Largest revenue contributor with EBITDA margins of 16-17%. Continued strength in domestic demand across QSR, dairy, and e-commerce packaging applications. Packaging and extrusion utilization at 80-85%, near nameplate capacity.
Injection Moulding: EBITDA margins of 13-14%, lower than packaging. Revenue contribution declined to 12.3% of revenue (from 15.6% YoY) as 60% of IM sales come from exports, which were disrupted by geopolitical tensions. Management views this as temporary and expects contribution to return to 15-16% within 1-2 quarters. Capacity utilization currently at 55-60%, providing headroom for growth without incremental capex.
Olive Ecopak (JV - not consolidated): Generated revenue of ₹17.22 crores and EBITDA of ₹4.61 crores in Q1 FY27. Business expanding in paper-based food packaging with a broadening product portfolio and customer base. Management expects FY27 revenue of ~₹90 crores ±₹5 crores and PAT break-even this year.
Company-Specific & Strategic Commentary
Capacity Expansion: Sleeving capacity expanded from 1,275 to 1,675 lakh units per annum, strengthening integrated packaging capabilities. Injection moulding capacity now at 5,800 MT following addition of 1,000 MT (5.8x since FY23). Current setup can support revenue of ₹420-430 crores.
Greenfield Expansion (Eastern India): Land of ~3.5 acres already procured in eastern India; investment currently on hold until existing capacity is more fully utilized. Phase I capex estimated at ₹25-30 crores with revenue potential of ₹80-100 crores; full-scale capacity could support ₹250-300 crores. Capex likely to commence next year, funded through internal accruals and long-term debt.
Renewable Energy: Entered into group captive wind-solar arrangement of ~1.9 MW, expected commissioning October 2026. Projected to meet ~30% of energy requirements with annual savings of ₹1.5-1.75 crores.
Marketing & Customer Engagement: Participated in leading exhibitions including Interpack (Germany), NRA (Chicago), and Aahar (Delhi) to deepen existing relationships and engage prospective customers globally.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue | ₹420-430 crores from current setup | Expected to be reached within next 12-18 months; growth from packaging (at 80-85% utilization) and injection moulding (at 55-60% utilization, room to grow) |
| EBITDA Margin | 15-16% steady state | As scale-up and capacity utilization improves across invested capacities |
| Debt Reduction | 15-20% reduction over next year | Debt to be reduced before committing to greenfield expansion; future capex to be a mix of internal accruals and long-term debt |
| Olive Ecopak Revenue | FY27: ~₹90 crores ±₹5 crores; FY28: ₹140-150 crores | Continued expansion in paper-based packaging; PAT break-even expected in FY27 |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical disruption to exports | 60% of injection moulding sales are exports; Q1 FY27 saw export revenue flat while IM revenue mix dropped from 15.6% to 12.3%. Management expects recovery in 1-2 quarters but continued volatility could persist. |
| Raw material price volatility | Polypropylene prices (common base material for both packaging and injection moulding) spiked ~10% during the quarter, compressing gross margins to ~38.3% vs 42.5% in Q4 FY26. Management expects normalization in 1-2 months provided no further escalations; gross margins should revert to 42.5-43.5% band. |
| Capacity constraints in packaging | Packaging and extrusion at 80-85% utilization with limited headroom; revenue potential capped at ~₹420-430 crores from current setup. Greenfield expansion (Phase I ₹25-30 crores) not yet committed, creating potential growth interruption if timing misaligns. |
Q&A Highlights
Segment Margins & Revenue Mix
- Question: What are the margin profiles of injection moulding vs packaging business? (Abhi Jain, AJ Capital)
- Answer: Injection moulding EBITDA margin is 13-14% while packaging is 16-17%. Packaging is the higher-margin business. IM revenue contribution fell to 12.3% this quarter because 60% of IM sales are exports, which were disrupted by geopolitical issues; this is temporary and expected to recover to 15-16% within 1-2 quarters. (Ramswaroop Thard)
Growth Trajectory & Long-Term Revenue Potential
- Question: How do you see growth after a flattish FY26, given revenue of ₹420-430 crores from current setup? (Abhi Jain, AJ Capital)
- Answer: Packaging demand remains strong across India with growth in online delivery, QSR formats, and dairy packaging. The current setup can support ₹420-430 crores in revenue, and the company has invested in land in eastern India for future expansion. Growth should resume as capacity utilization improves over the next 6-12 months. (Ramswaroop Thard)
Steady-State Margin Outlook
- Question: What EBITDA margins should be expected over the next 2-3 years as the mix shifts toward lower-margin injection moulding? (Abhi Jain, AJ Capital)
- Answer: As the company scales up and utilizes invested capacities, company-level EBITDA margins should settle in the 15-16% range. (Ramswaroop Thard)
Capacity Utilization & Revenue Potential
- Question: Can the ₹420-430 crores revenue level be reached by FY27, and what are current utilization levels? (Nishita Shanklesha, Sapphire Capital)
- Answer: Management is positive about reaching these numbers this year if markets stay balanced, but surely by next year. Packaging and extrusion are at 80-85% utilization; injection moulding at 55-60%. Utilization varies by seasonality. (Ramswaroop Thard)
Greenfield Capex Plans
- Question: What is the capex plan for the new eastern India facility and what revenue can it generate? (Nishita Shanklesha, Sapphire Capital; Amit Mehendale, RoboCapital)
- Answer: Land of ~3.5 acres is secured; no investment in the current year. Phase I capex would be ₹25-30 crores generating ₹80-100 crores revenue; full-scale capacity can reach ₹250-300 crores. Facility will handle a combination of packaging and injection moulding. Capex timing depends on reaching existing capacity utilization. (Ramswaroop Thard)
Debt Reduction & Funding Strategy
- Question: Will debt be repaid before the expansion, and how will future capex be funded? (Amit Mehendale, RoboCapital)
- Answer: The goal is to reduce debt by 15-20% over the next year (roughly ₹10-15 crores), then fund expansion through a combination of internal accruals and long-term debt rather than increasing working capital requirements. (Ramswaroop Thard)
Olive Ecopak JV Performance
- Question: How is the Olive Ecopak JV performing and what are the expectations for the next 2 years? (Amit Mehendale, RoboCapital)
- Answer: Q1 revenue was ₹17.22 crores with EBITDA of ₹4.61 crores. FY27 guidance is ~₹90 crores ±₹5 crores with PAT at least break-even. FY28 target is ₹140-150 crores of revenue. JV is not consolidated into Rajshree's financials. (Ramswaroop Thard)
Raw Material Prices & Gross Margin
- Question: How are raw material prices affecting gross margins, and will they recover to Q3/Q4 FY26 levels (42.5-43.5%)? (Agastya Dave, CAO Capital)
- Answer: Polypropylene prices dropped ~10% a month ago but spiked again due to renewed tensions. Gross margin compression to ~38.3% is entirely attributable to raw material escalation; mix change was not significant. Margins should return to the 42.5-43.5% band as raw material prices normalize, likely within 1-2 months barring further escalations. (Ramswaroop Thard)
Nature of Job Work Expenses
- Question: What is the nature of ₹12.8 crores of job work expenses in FY26 - is it outsourcing of capacity? (Agastya Dave, CAO Capital)
- Answer: Job work charges relate to a toll manufacturing agreement for injection moulding, where a third party works 100% for Rajshree. Their capacity utilization is currently at 55-60%. (Ramswaroop Thard)
Key Takeaway
Rajshree Polypack delivered its highest-ever quarterly revenue of ₹102.91 crores in Q1 FY27 (+24.7% YoY), with EBITDA up 36.8% to ₹16.52 crores (16.05% margin) and PAT up 76.8% to ₹7.25 crores, driven by strong domestic recovery (domestic revenue ₹91.19 crores, +31.9% YoY) while exports remained flat at ₹11.72 crores due to geopolitical headwinds. Strategy centers on scaling injection moulding (capacity 5,800 MT, utilization at 55-60%) to drive the next leg of growth toward the ₹420-430 crores revenue potential of the current setup, while expanding sleeving capacity to 1,675 lakh units/annum and commissioning a 1.9 MW wind-solar captive plant (October 2026) expected to save ₹1.5-1.75 crores annually. Olive Ecopak JV (not consolidated) generated ₹17.22 crores revenue with EBITDA of ₹4.61 crores and is tracking toward ₹90±5 crores for FY27 with PAT break-even. Key near-term watch points include raw material (polypropylene) price normalization to recover gross margins to the 42.5-43.5% band, recovery in injection moulding export sales, and the timing of the ₹25-30 crores Phase I greenfield capex in eastern India as existing capacity fills up.